CLEVELAND, April 2, 2021 /PRNewswire/ -- S4 Medical
moves a step closer in developing the most comprehensive solution
to protect the esophagus from thermal injury during catheter
ablation procedures for atrial fibrillation (AF) with the closing
of their Series A financing. Three new shareholders – Jobs Ohio,
Angel Physician Fund, and an unnamed strategic investor -- have
come on board, along with existing investors, to help accelerate
efforts towards commercialization.
The Series A funding will be used primarily to conduct the
company's Investigational Device Exemption study, which is
estimated to begin in July 2021. The
company has already achieved several important milestones including
first-in-human testing, securing intellectual property, and
demonstration of compatibility with electrophysiology systems.
S4 Medical was cofounded by Dr. Emile
Daoud of The Ohio State
University, and William
Fuller. The company's primary product is the
esolution catheter – a patented device intended to safely
deviate and protect the esophagus during catheter ablation for
AF.
Cofounder, Chief Medical Officer, coinventor of the device, and
Electrophysiology Section Chief at The Ohio
State University, Emile
Daoud, MD, says: "We are thrilled at the closing of this
investment and excited to begin our pivotal trials. If successful,
the esolution device will be well received by
electrophysiologists as an added benefit for managing patients
undergoing AF ablation."
Since its founding in late 2017, S4 has moved quickly and
achieved significant milestones towards bringing the
esolution device to market. "S4 offers a world-class
solution to a big problem and a large market opportunity," says
cofounder and CEO William Fuller.
"Our existing and new investors see the promise of S4's solution
and the possibility to provide additional safety to catheter
ablation procedures."
"We immediately recognized the value of S4's technology and are
pleased to not only participate in this financing but also to
support S4 as it goes into its clinical studies," says Manish Bhandari, MD, managing partner of the
Angel Physician Fund of Cincinnati, which comes into the round with a
wealth of clinical and entrepreneurial experience.
S4 board member and managing director of the Columbus-based Ohio Innovation Fund (OIF),
Bill Baumel, adds: "OIF confidently
reinvests in S4 Medical and its mission of bringing cutting edge
research to market – with the aim of making a huge positive impact
on people's lives."
"AF ablation is a large and fast-growing market," says
Hardik Desai, senior partner at
Jumpstart Inc, of Cleveland, Ohio,
"and we're happy to support S4 as they enter the clinical phase
towards commercialization to address this critical unmet need."
Jumpstart, which focuses on early stage investing and has been
involved with S4 from the start, also reinvested in the Series A
round.
About S4:
S4 Medical Corp. is a medical device company focused on
innovative solutions for cardiac procedures. The company's main
focus is a simple, yet comprehensive solution for reducing
complications to the esophagus during catheter ablation treatment
for atrial fibrillation. S4's team is motivated by providing
advanced solutions for superior healthcare. For more information,
visit S4 at www.S4medical.com on LinkedIn and Twitter.
Media Contact:
William Fuller
440.279.8091
306639@email4pr.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/s4-medical-closes-series-a-financing-301261376.html
SOURCE S4 Medical